MedPath

The Therapeutic Effect of Co-administration of Pentoxifylline and Zinc in Men With Idiopathic Asthenozoospermia

Early Phase 1
Conditions
Men Infertility
Interventions
Registration Number
NCT05178953
Lead Sponsor
Arak University of Medical Sciences
Brief Summary

The aim of this study was to investigate the therapeutic effect of co-administration of pentoxifylline and zinc on sperm apoptosis in men with idiopathic infertility

Detailed Description

This study is being performed as a double-blind randomized clinical trial on idiopathic infertile men referred to the infertility clinic of Shafa Clinic. Patient satisfaction, non-use of contraceptives, men aged 25 to 43 years, and idiopathic infertility according to WHO criteria (World Health, 2010) are our study criteria. Any medication that may affect the course of spermatogenesis should be discontinued during the study. Semen samples are taken from patients (before and after interventions) and apoptosis tests are performed on semen samples.

Recruitment & Eligibility

Status
UNKNOWN
Sex
Male
Target Recruitment
160
Inclusion Criteria
  • infertile men
  • have had at least one year of unprotected intercourse infertility
  • asthenozoospermia
Exclusion Criteria
  • Men with varicocele
  • Hypersensitivity to pentoxifylline & zinc,
  • pelvic organic pathologies
  • congenital adrenal hyperplasia
  • thyroid dysfunction
  • Cushing's syndrome
  • hyper prolactinemia
  • androgen secreting neoplasia
  • severe hepatic
  • pancreatitis
  • kidney diseases
  • gallbladder diseases
  • Patients with alcohol consumption
  • Patients who use cigarettes and drugs

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Zinc Sulfate groupZinc Sulfate 220 mg CapsulesInfertile men referred to an infertility treatment center who have had unprotected sex for at least one year have not had normal fertility in their partner. These men are all married. According to WHO criteria, sperm motility abnormalities are observed in these patients. Candidates receive one zinc sulfate tablet(229 mg) daily for 3 month,(Zinc Sulfate 220mg Capsules) Other Names: zinc sulfate
pentoxifylline groupPentoxifyllineGroup 1: Patients receiving pentoxifylline (TRENTAL 400 mg tablets, OSPS; 400 mg, twice daily) Infertile men referred to an infertility treatment center who have had unprotected sex for at least one year have not had normal fertility in their partner. These men are all married. According to WHO criteria, sperm motility abnormalities are observed in these patients. These volunteers receive two pentoxifylline tablets(400 mg) daily for 3 month, (TRENTAL 400 mg modified release tablets, OSPS; 400 mg ,two times daily) Other names: Trental
pentoxifylline+ zinc groupZinc Sulfate 220 mg CapsulesInfertile men referred to an infertility treatment center who have had unprotected sex for at least one year have not had normal fertility in their partner. These men are all married. According to WHO criteria, sperm motility abnormalities are observed in these patients. Candidates receive one zinc sulfate(220mg) tablet+ two pentoxifylline tablets(400 mg) daily for 3 month (TRENTAL 400 mg modified release tablets, OSPS; 400 mg +Zinc Sulfate 220mg Capsules) Other Names: zinc sulfate
pentoxifylline+ zinc groupPentoxifyllineInfertile men referred to an infertility treatment center who have had unprotected sex for at least one year have not had normal fertility in their partner. These men are all married. According to WHO criteria, sperm motility abnormalities are observed in these patients. Candidates receive one zinc sulfate(220mg) tablet+ two pentoxifylline tablets(400 mg) daily for 3 month (TRENTAL 400 mg modified release tablets, OSPS; 400 mg +Zinc Sulfate 220mg Capsules) Other Names: zinc sulfate
Primary Outcome Measures
NameTimeMethod
lipid proxidationOne week

Malondialdehyde (nmol/mL), is measured using related experimental kits

sperm concentration1 day

count of sperm(In per million - with the help of a neobar slide and microscopic observation

spem motility1 day

motility of sperm: Calculate the percentage of motile sperm using microscopic observation

reactive oxygen speciesOne week

eactive oxygen species (ROS (RLU/s)), is measured using related experimental kits

FSH hormonOne week

FSH (IU / L) is measured from the blood serum of volunteers using ELISA kit

sperm morphology1 day

Calculate the percentage of sperm with a normal shape with the help of Papanic staining

total antioxidant capacityOne week

total antioxidant capacity (TAC (/m / l)) is measured using related experimental kits

LH hormonOne week

LH (IU / L) is measured from the blood serum of volunteers using ELISA kit

testosteron hormon [ Time Frame: One week after starting the medication ] testosteroneOne week

testosterone (nanomolar per liter) is measured from the blood serum of volunteers using ELISA kit

(Tissue necrosis Factor)One week

TNF α( Tissue necrosis Factor) (pg/mL) as an inflammatory factor is measured using related experimental kit

interleukin-6One week

interleukin-6 (IL-6)/(pg/mL) as an inflammatory factor is measured using related experimental kit

Sperm DNA Fragmentation Assay(SDFA)One week

DNA fragmentation is assessed using an SDFA kit and microscopic observations (as a percentage of damaged sperm).

Secondary Outcome Measures
NameTimeMethod
BAX expression3 month

BAX expression \[ Time Frame: 3 months \]

expression of BAX gen(in p.c) using real-time PCR and Western blot

caspase 3 expression3 months

expression of caspase 3 gen(in p.c) using real-time PCR and Western blot

Bcl2 expression3 months

Bcl-2 gen(in p.c) using real-time PCR and Western blot

Trial Locations

Locations (2)

Arak university of medical science

🇮🇷

Arak, Markazi, Iran, Islamic Republic of

Infertility Center

🇮🇷

Arak, Markazi, Iran, Islamic Republic of

© Copyright 2025. All Rights Reserved by MedPath